- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Tempus AI, Inc. Class A Common Stock(TEM)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TEM
11/16/2026: TEM (1-star) is a SELL. SELL for 1 day. Simulated Profits (-19.59%). Updated daily EoD!
Tempus AI is a healthcare technology company that combines molecular diagnostic testing with artificial intelligence to advance precision medicine. The company exhibits strong revenue growth driven by expanding diagnostic volumes and high-margin data-licensing agreements with life sciences partners. Its primary investment thesis centers on scaling its proprietary multimodal data platform to transform clinical decision-making and drug discovery. However, key risks include ongoing net losses, high stock-based compensation, and intense competition in the healthcare analytics space. The stock suits growth-oriented investors willing to tolerate high volatility while monitoring bottom-line margin improvement and regulatory developments.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Tempus delivers rapid top-line revenue expansion and operates at the intersection of high-growth healthcare technology and artificial intelligence. |
| Momentum investor | Strong fit while signal remains positive | Strong quarterly revenue growth and high market interest make the stock attractive when technical and sentiment indicators trend upward. |
| Value investor | Weak fit | The company currently registers net losses and trades on forward growth expectations rather than traditional value metrics. |
| Dividend investor | Weak fit | Tempus does not pay dividends, opting instead to reinvest earnings into business expansion. |
| Low-risk investor | Weak fit | High share price volatility and ongoing bottom-line unprofitability expose investors to considerable risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock experiences significant price swings driven by market sentiment and growth expectations. |
| Valuation risk | Medium / high | Pricing relies heavily on sustaining aggressive future revenue and margin expansion. |
| Competition risk (AI and healthcare data) | Medium / high | Intense competition from established healthcare data giants and diagnostic labs could pressure margins. |
| Business quality | Medium | The core platform demonstrates strong revenue retention and proprietary data scale, offset by net losses. |
| Dividend income | Low / none | Income-focused investors receive no dividend yield from the equity. |
| Execution risk | Medium / high | Successfully integrating recent acquisitions and scaling profitability requires precise operational management. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.06B USD | Price to earnings Ratio - | 1Y Target Price 89.56 |
Price to earnings Ratio - | 1Y Target Price 89.56 | ||
Volume (30-day avg) 6.6M shares | Beta 3.61 | 52 Weeks Range 40.77 - 89.09 | Updated Date 11/15/2026 |
52 Weeks Range 40.77 - 89.09 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.06 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 63.9%
- Active BUY / eligible
- 69 / 108
- 30-Day BUY Count Change
- +31
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Health Information Services
- BUY participation
- 100.0%
- Active BUY / eligible
- 4 / 4
- 30-Day BUY Count Change
- +1
Eligible universe: 4 stocks.
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -48.13% | Avg. Invested days 19 | Today’s Advisory SELL |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Diagnostics | Clinical molecular diagnostic testing services, including oncology profiling, hereditary cancer screening, and MRD tests. | This segment generates the lion's share of total revenue through direct volume-based testing fees paid by healthcare providers and insurers. |
| Data and Applications | Licensing proprietary multimodal clinical databases (Insights) and providing software applications (Lens/Hub) to life sciences firms. | This high-margin segment monetizes aggregated healthcare data to help pharmaceutical companies discover drugs and match patients to clinical trials. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 13.85B | Price to Sales(TTM) 8.65 |
Enterprise Value 13.85B | Price to Sales(TTM) 8.65 | ||
Enterprise Value to Revenue 9.18 | Enterprise Value to EBITDA - | Shares Outstanding 177.36M | Shares Floating 125.67M |
Shares Outstanding 177.36M | Shares Floating 125.67M | ||
Percent Insiders 37.11 | Percent Institutions 58.16 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

